Back to News
Market Impact: 0.32
Sagimet's Denifanstat Delivers Positive 52-Week Results In Acne Trial
Source: Nasdaq
Healthcare & Biotech
Sagimet Biosciences reported positive 52-week Phase 3 open-label extension results for denifanstat, based on a study conducted by license partner Ascletis BioScience in patients with moderate-to-severe acne vulgaris. The long-term positive clinical data support denifanstat's potential in acne treatment and could be a favorable catalyst for Sagimet shares.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.48
Ticker Sentiment
SGMT0.72
More News
- Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial
- Walgreens owner nears $9 billion deal to sell Boots chain- WSJ
- Why is Toho stock volatile today?
- Lilly’s Foundayo shows cardiovascular safety in diabetes trial
- Nvidia is approaching a breakout level. Plus, what we want to see from Micron
- Some Oura IPO Investors Were Said to Push Back Citing Valuation
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- How to Track Guidance Changes Across a Coverage List With AI
- Stop Treating AI Like a Chatbot: What Are Agents, SubAgents, MCP, and Skills, and How Do They Actually Work?